Company Encyclopedia
View More
name
abrdn Healthcare Opportunities
THQ.US
News
View More

BUZZ-Abivax jumps on media reports of Eli Lilly takeover bid

BUZZ-Abivax jumps on media reports of Eli Lilly takeover bid

Reuters·
US
LLY
+1.38%
Reuters·
US
LLY
+1.38%

Congress Asset Management Co. Sells 2,547 Shares of Eli Lilly and Company $LLY

Congress Asset Management Co. reduced its stake in Eli Lilly and Company by 14.6% in Q3, selling 2,547 shares. Eli Lilly's stock opened at $1,071.35, with a 12-month high of $1,111.99. The company reported Q3 earnings of $7.02 per share, exceeding estimates. Positive sentiment surrounds Eli Lilly's obesity drug trials and FDA filings, while pricing pressure in Canada may impact margins.

Market Beat·
US
LLY
+1.38%
Market Beat·
US
LLY
+1.38%

European shares steady after record close entering holiday week

European shares held steady on Monday after a record-high close, with tech and commodity-linked stocks providing support. The STOXX 600 was at 587.28, with major regional markets in London and France down 0.3%. Tech shares gained 0.6%, and commodity-linked sectors traded higher. Abivax jumped 10% on takeover rumors by Eli Lilly.

Reuters·
US
ABVX
+1.17%
US
LLY
+1.38%
Reuters·
US
ABVX
+1.17%
US
LLY
+1.38%

Danaher Corporation $DHR is Arthur M. Cohen & Associates LLC's 6th Largest Position

Arthur M. Cohen & Associates LLC reduced its stake in Danaher Corporation by 15.5% in Q3, holding 159,002 shares worth $31.5M. Danaher is the firm's 6th largest position. Analysts have set new price targets, with a consensus rating of "Moderate Buy" and a target price of $248.25. Insiders sold 30,248 shares valued at $6.6M recently. Danaher stock opened at $224.78, with a market cap of $158.77B.

Market Beat·
US
DHR
+0.22%
Market Beat·
US
DHR
+0.22%

Pharma's $370 Billion Bet On America: The ETF Plays For 2026

In 2025, the U.S. pharmaceutical industry rebounded with a $370 billion investment pledge, driven by tariff threats and MFN pricing deals. Major firms like Eli Lilly expanded U.S. manufacturing. ETFs such as iShares U.S. Pharmaceuticals ETF offer diversified exposure to this growth. The industry is entering an investment super-cycle, with significant capital influx from major drugmakers, enhancing profitability and reinforcing the domestic drug supply chain. The Trump administration's trade policies and FDA's PreCheck program are key catalysts for this investment surge.

Talkmarkets·
US
LLY
+1.38%
Talkmarkets·
US
LLY
+1.38%
© 2025 Longbridge｜Disclaimer